These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1360945)

  • 21. [Acquisitions in the therapeutic use of H2 antagonists: a critical study (author's transl)].
    Vallot T; Mignon M
    Gastroenterol Clin Biol; 1981 Oct; 5(10):905-16. PubMed ID: 6117496
    [No Abstract]   [Full Text] [Related]  

  • 22. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
    Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
    Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
    Chassany O; Bergmann JF
    Rev Prat; 1998 Apr; 48(8):893-8. PubMed ID: 11767336
    [No Abstract]   [Full Text] [Related]  

  • 24. Peptic ulcer disease in the elderly.
    Cryer B; Feldman M
    Semin Gastrointest Dis; 1994 Oct; 5(4):166-78. PubMed ID: 7834250
    [No Abstract]   [Full Text] [Related]  

  • 25. [Action of histamine H2 receptor blockaders on gastric motor function in duodenal peptic ulcer].
    Shcherbak VV; Glubochenko VG; Zaĭdman VE
    Klin Med (Mosk); 1984 Jun; 62(6):94-6. PubMed ID: 6147438
    [No Abstract]   [Full Text] [Related]  

  • 26. [The characteristics of the course and treatment of patients with hypertension combined with gastric and duodenal ulcers and chronic gastroduodenitis].
    Ievtushenko OV
    Lik Sprava; 1999 Jul; (5):86-9. PubMed ID: 10822687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of the symptomatic clinical efficacy of ranitidine in benign gastroduodenal pathology].
    Rizzi B; Villa E; Di Sclafani E; Terni E; Proserpio L; Bonfanti R; Komla-Ebri K
    Clin Ter; 1985 Jun; 113(6):447-55. PubMed ID: 4028651
    [No Abstract]   [Full Text] [Related]  

  • 28. A comparison of nizatidine with the three other histamine receptor antagonists for duodenal ulcer therapy.
    Lima M; Holdcroft C
    Nurse Pract; 1989 Feb; 14(2):41-2. PubMed ID: 2564655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of an oral morning dose of nizatidine and ranitidine on gastric acid secretion in duodenal ulcer patients.
    Lazzaroni M; Bianchi Porro G
    Hepatogastroenterology; 1989 Dec; 36(6):490-3. PubMed ID: 2575571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The diagnostic value of the histamine test in studying the gastric juice of patients with duodenal peptic ulcer].
    Starostenko IN
    Ter Arkh; 1992; 64(2):45-8. PubMed ID: 1509382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical perspectives of drugs inhibiting acid secretion: histamine H2 antagonists.
    Bauerfeind P; Popien J; Traber M; Bumm R; Cucala M; Dorta G; Blum AL
    Scand J Gastroenterol Suppl; 1986; 125():42-9. PubMed ID: 2881346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostaglandins for duodenal ulcer.
    Lam SK
    Clin Invest Med; 1987 May; 10(3):232-7. PubMed ID: 2887323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease.
    Kamada T; Hata J; Kusunoki H; Sugiu K; Ito M; Tanaka S; Kawamura Y; Chayama K; Haruma K
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():99-104. PubMed ID: 15943855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Changes in therapy of duodenal ulcers. The European Gastro-Club 1983 discusses new pathophysiologic and epidemiologic data referring to drug and surgical therapy].
    Demling L
    Fortschr Med; 1983 Dec; 101(47-48):2195-6. PubMed ID: 6142849
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of acid inhibition on Campylobacter pylori.
    Blanco M; Pajares JM; Jimenez ML; Lopez-Brea M
    Scand J Gastroenterol Suppl; 1988; 142():107-9. PubMed ID: 2901784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The effects of nizatidine and misoprostol on peptic activity and gastric mucus].
    Grassi SA; Vianello F; Germanà B; Dal Santo P; Faggian D; Battaglia G; Plebani M; Di Mario F; Naccarato R
    Medicina (Firenze); 1990; 10(1):29-31. PubMed ID: 1974318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A single night-time dose of H2 antagonists: a novelty in the treatment of duodenal ulcer].
    Dammann HG; Walter TA; Müller P; Simon B
    Clin Ter; 1985 Jun; 113(6):435-42. PubMed ID: 2863028
    [No Abstract]   [Full Text] [Related]  

  • 39. The effect of ranitidine hydrochloride, a new histamine H2-receptor antagonist, on intrinsic factor secretion.
    Mohammed R; Clark JS; Adams JF; Hearns JB; Crean GP
    Clin Ther; 1981; 4(2):118-20. PubMed ID: 6117373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of gastric acid rebound after stopping a successful short-term course of nizatidine in duodenal ulcer patients.
    Savarino V; Mela GS; Zentilin P; Sumberaz A; Bonifacino G; Celle G
    Am J Gastroenterol; 1991 Mar; 86(3):281-4. PubMed ID: 1671805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.